Top25-SA-Banner

Analysts Are Bullish on These Healthcare Stocks: Esperion (ESPR), Myovant Sciences (MYOV)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Esperion (NASDAQ:ESPR) and Myovant Sciences (NYSE:MYOV) with bullish sentiments.

Esperion (ESPR)

Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Esperion today and set a price target of $95. The company’s shares opened today at $40.41, close to its 52-week low of $33.06.

According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 11.9% and a 39.1% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.

Esperion has an analyst consensus of Moderate Buy, with a price target consensus of $73.23.

See today’s analyst top recommended stocks >>

Myovant Sciences (MYOV)

In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Myovant Sciences. The company’s shares opened today at $23.47, close to its 52-week high of $25.54.

According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 15.7% and a 57.7% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Voyager Therapeutics Inc.

Currently, the analyst consensus on Myovant Sciences is a Moderate Buy with an average price target of $44.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.